AI-based test method for identifying respiratory sensitizing agents
CompanySenzaGen, Lund, Sweden
To identify respiratory sensitizers during the efficacy and safety testing of new medications, the company SenzaGen has developed the AI-based test procedure GARD®air. At the beginning, human dendritic cells, which simulate part of the critical immune system, are brought into contact with the active ingredient to be examined. A machine learning platform then analyses the gene expression pattern of the test sample and compares it to 28 biomarkers associated with allergic respiratory reactions. The method can reliably distinguish inhalation allergens from non-sensitizers with a specificity of 95% and therefore proves to be a valuable test method for identifying allergenic active ingredients early in drug development and rejecting them as potential candidates. At the same time, the assay prevents incorrect evaluation of non-sensitizing active ingredients. GARD®air delivers meaningful results within 4–8 weeks and can thus help to accelerate the development and approval of new drugs.
GARD®air. A predictive test for chemical respiratory sensitizers
info@senzagen.com
Added on: 11-21-2023
[1] https://senzagen.com/gardair/
